This is the authors' abstract. We don't add key points for this paper.
This real-world study confirmed the efficacy and safety of three different CGRP mAbs for prophylactic treatment of patients with migraine.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Suzuki et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: